Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
نویسندگان
چکیده
منابع مشابه
Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
The advances in recombinant DNA technology have led to an improvement in the properties of currently available long-acting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a promising future in clinical use. When compared to its rival basal insulin analogs, a longer duration of action and lower incidence of hypoglycem...
متن کاملInsulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
This editorial discusses a novel basal insulin analog, insulin degludec. It describes the limitations of existing basal insulins, and builds the case for a better analog. The editorial discusses the evidence to support the efficacy, safety, tolerability, and flexibility of degludec, and assesses its utility as part of a person-centered approach to diabetes management.
متن کاملIn search of the ideal basal insulin: Does the new‐generation ultra‐long‐acting insulin, degludec, provide the answer?
Improving glycemic control without increasing the risk of hypoglycemia has been the main crux of the management of patients with both type 1 and type 2 diabetes mellitus. Nocturnal hypoglycemia and hypoglycemic unawareness has long been a well-recognised contributor to morbidity and mortality in type 1 diabetes. Hypoglycemia becomes a progressively frequent clinical problem as patients approach...
متن کاملInsulin degludec as an ultralong-acting basal insulin once a day: a systematic review
BACKGROUND Insulin degludec (IDeg) is a neutral, ultralong-acting new generation basal insulin analog developed by NovoNordisk currently in Phase III clinical development. IDeg offers a duration of action of more than 42 hours in adults, much longer than current basal insulin formulations. OBJECTIVE The aim of this review is to assess the efficacy and safety data of IDeg in the treatment of t...
متن کاملSwitching from Twice-Daily Basal Insulin Injections to Once-Daily Insulin Degludec Injection for Basal-Bolus Insulin Regimen in Japanese Patients with Type 1 Diabetes: A Pilot Study
The aim of this study was to investigate the efficacy of insulin degludec used for basal-bolus insulin regimen after switching from twice-daily basal insulin in Japanese patients with type 1 diabetes mellitus. The subjects were 22 type 1 diabetes patients treated with basal-bolus insulin regimen with twice-daily basal insulin. Basal insulin was switched to once-daily injection of insulin deglud...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Medicine Insights: Endocrinology and Diabetes
سال: 2012
ISSN: 1179-5514,1179-5514
DOI: 10.4137/cmed.s9494